|
|
|
|
Teva buys rival Ratiopharm
ISRAELs Teva Pharmaceutical Industries won the battle for German generic drug maker Ratiopharm, paying an enterprise value of 3,625bn to fix the industry leaders weakness in the worlds second-largest generics market.Tevas bid, which beat US drugs leader...
|
|
|
Teva In $5B Deal To Buy Ratiopharm
FRANKFURT -- Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH - in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.The deal, which is being paid for with cash and...
|
|
|
Teva to buy German generic drug maker Ratiopharm
FRANKFURT (AP) Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.Teva Pharmaceutical Industries Ltd.'s...
|
|
|
Teva to buy German generic drug maker Ratiopharm
FRANKFURT (AP) -- Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH - in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.Teva Pharmaceutical Industries Ltd.'s...
|
|
|
Teva to buy Ratiopharm for nearly $5 billion
Teva, which beat US drugs powerhouse Pfizer and Iceland's Actavis in the race for Ratiopharm, said the combined company would have had 2009 revenues of $16.2 billion, up from Teba's own sales of $13.9 billion.Put on the auction block by Germany's Merckle...
|
|
|
Teva to buy German generic drug maker Ratiopharm
FRANKFURT Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.Teva Pharmaceutical Industries Ltd.'s successful bid...
|
|
|
Teva to buy German generic drug maker Ratiopharm
FRANKFURT (AP) -- Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH - in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.Teva Pharmaceutical Industries Ltd.'s...
|
|
|
It's a very good fit for Teva, and the market will view it positively
Teva, which beat U.S.drugs powerhouse Pfizer (PFE.N Put on the auction block by Germany's Merckle family as its business empire crumbled, Ratiopharm vies with Stada (STAGn. DE None of the other companies have yet commented on the deal. Trade in Teva...
|
|
|
Teva buys Ratiopharm
Israeli drug maker Teva, number four in Germany's generics market, will jump straight to the top spot acquisition Email Please enter a valid e-mail address Please enter a comma delimited list of valid e-mail addresses Other ways of sharing: License this story...
|
|
|
Teva Provides Update on Generic Temodar
Teva's Safe Harbor Statement under the U.Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current...
|
|
|
Teva Provides Update on Generic Temodar
Teva's Safe Harbor Statement under the U.Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current...
|
|
|
Teva to launch Laquinimod lupus clinical trial: The firm's new Multiple Sclerosis drug may be able to treat other illnesses as w
In the next few weeks Teva will begin recruiting patients for a Phase IIa clinical trial for Laquinimod for treating lupus nephritis, which affects the kidneys, and lupus arthritis, which affects joints.The trial is slated to begin in the summer. Teva has...
|
|
|
Some with MS already use estriol - if they can get it [The Philadelphia Inquirer]
12--An untold number of women with multiple sclerosis are not waiting to see if estriol wins approval as a therapy before using it.But these days, getting a prescription for the decades-old generic drug can be an ordeal. Estriol's innocuousness -- no shots...
|
|
|
5-Star Stocks Poised to Pop: Teva Pharmaceutical
Based on the aggregated intelligence of 150,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug specialist Teva Pharmaceutical Industries (Nasdaq: TEVA) has earned a coveted five-star ranking.With that in...
|
|
|
Teva Pharmaceutical Industries Ltd. Announces new Chairman to its Board of Directors.
Generic Drug maker, Teva Pharmaceutical Industries Ltd.(NASDAQ:TEVA) says it has chosen Vice Chairman, Dr. Phillip Frost to serve as Chairman. North Bergen, New Jersey 3/09/2010 04:43 PM GMT (TransWorldNews) Teva Pharmaceutical Industries Ltd.(NASDAQ...
|
|
|
Israel's TEVA a Headache for Drug Firms, Rx for Investors
Follow Israel news on and.(IsraelNN.com) Israel-based Teva Pharmaceuticals, besides making generic drugs, has made lots of people millionaires. Sixteen years ago, its stock was worth $3.02 a share. This week, it is trading at a new record high of...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Scleros
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the escape_start39;221 patent) which protects the target product profile for its PI-2301 peptide...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Scleros
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the escape_start39;221 patent) which protects the target product profile for its PI-2301 peptide...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Scleros
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the escape_start39;221 patent) which protects the target product profile for its PI-2301 peptide...
|
|
|
Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis
Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...
|
|
|
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...
|
